Imaging approaches with advanced prostate cancer: Techniques and timing

Canadian Journal of Urology

Volumn 21, Issue , 2014, Pages 42-47

  Leung, David ^a   Krishnamoorthy, Saravanan ^a   Schwartz, Lawrence ^a   Divgi, Chaitanya ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Androgen receptors; Castration resistant prostate cancer; CRPC; FDG; Molecular imaging; MRI; NaF; PET

Indexed keywords

CANCER STAGING; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE MANAGEMENT; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSTATIC NEOPLASMS; SCINTISCANNING; TIME; TRENDS;

DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIONUCLIDE IMAGING; TIME FACTORS;

EID: 84911074795     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Moore CM, Robertson NL, Arsanious N et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013;63(1):125-140.
2. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004;172(5 Pt 2): S42-S46.
3. Perlmutter MA, Lepor H. Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy. Urology 2008;71(3):501-505.
4. Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 2000;31(6):578-583.
5. Imbriaco M, Larson SM, Yeung HW et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 1998;4(7):1765-1772.
6. Dennis ER, Jia X, Mezheritskiy IS et al. Bone scan index: a quantitative treatment response biomarker for castrationresistant metastatic prostate cancer. J Clin Oncol 2012;30(5): 519-524.
7. Ulmert D, Kaboteh R, Fox JJ et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. Eur Urol 2012; 62:78-84.
8. National Oncologic Pet Registry. Available from URL: http://www.cancerpetregistry.org/. Accessed December 29, 2013.
9. Even-Sapir E, Metser U, Mishani E et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mtcmdp planar bone scintigraphy, single-and multifield-of-view SPECT, 18F-fluoride pet, and 18F-fluoride PET/CT. J Nucl Med 2006;47(2):287-297.
10. Iagaru A, Mittra E, Dick DW, Gambhir SS. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)f NaF PET/CT, and (18)FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol 2012;14(2):252-259.
11. Scher HI, Morris MJ, Kelly WK et al. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005;11(14):5223-5232.
12. Schöder H, Herrmann K, Gönen M et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005;11(13):4761-4769.
13. Morris MJ, Akhurst T, Larson SM et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005;11(9):3210-3216.
14. Tolvanen T, Yli-Kerttula T, Ujula T et al. Biodistribution and radiation dosimetry of [(11)C]choline: a comparison between rat and human data. Eur J Nucl Med Mol Imaging 2010;37(5):874-883.
15. Picchio M, Spinapolice EG, Fallanca F et al. [11C]choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012;39(1):13-26.
16. U.S. Food and Drug Administration (FDA). Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319201.htm?source=govdelivery. Accessed December 29, 2013.
17. Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 2012;15(1):45-55.
18. Beheshti M, Vali R, Waldenberger P et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008;35(10):1766-1774.
19. Oyama N, Akino H, Kanamaru H et al. 11c-acetate pet imaging of prostate cancer. J Nucl Med 2002;43(2):181-186.
20. Oyama N, Miller TR, Dehdashti F et al. 11C-acetate pet imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003;44(4):549-555.
21. Fricke E, Machtens S, Hofmann M et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003;30(4):607-611.
22. Yu EY, Muzi M, Hackenbracht JA et al. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med 2011; 36(3):192-198.
23. Matthies A, Ezziddin S, Ulrich EM et al. Imaging of prostate cancer metastases with 18f-fluoroacetate using pet/ct. Eur J Nucl Med Mol Imaging 2004;31(5):797.
24. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F-or 11C-acetate, and 18F-or 11C-choline. J Nucl Med 2011;52(1):81-89.
25. Brandes SJ, Katzenellenbogen JA. Fundamental considerations in the design of fluorine-18 labeled progestins and androgens as imaging agents for receptor-positive tumors of the breast and prostate. Int J Rad Appl Instrum B 1988;15(1):53-67.
26. Larson SM, Morris M, Gunther I et al. Tumor localization of 16beta-18F-fluoro-5-alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004;45(3):366-373.
27. Dehdashti F, Picus J, Michalski JM et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005;32(3):344-350.
28. Manyak MJ. Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev Anticancer Ther 2008;8(2): 175-181.
29. Pucar D, Sella T, Schöder H. The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 2008;18(1):87-97.
30. Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006;3(4):216-225.
31. Pandit-Taskar N, O'Donoghue JA, Morris MJ et al. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med 2008;49(7):1066-1074.
32. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol 2013;31(2):144-154.
33. Evans MJ, Smith-Jones PM, Wongvipat J et al. Noninvasive measurement of androgen receptor signaling with a positronemitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 2011;108(23):9578-9582.
34. Afshar-Oromieh A, Haberkorn U, Hadaschik B et al. PET/MRI with a (68)Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging 2013;40(10):1629-1630.
35. Afshar-Oromieh A, Zechmann CM, Malcher A et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18) F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41(1):11-20.
36. Barrett T, Gill AB, Kataoka MY et al. DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study. Magn Reson Med 2012;67(3):778-785.
37. Michoux N, Simoni P, Tombal B et al. Evaluation of DCE-MRI post-processing techniques to assess metastatic bone marrow in patients with prostate cancer. Clin Imaging 2012;36(4):308-315.
38. Luboldt W, Kufer R, Blumstein N et al. Prostate carcinoma: diffusion weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology 2008;249(3):1017-1025.
39. Nakanishi K, Kobayashi M, Nakaguchi K et al. Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusionweighted images. Magn Reson Med Sci 2007;6(3):147-155.
40. Lecouvet FE, El Mouedden J, Collette L et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc-99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 2012;62(1):68-75.
41. Lee KC, Bradley DA, Hussain M et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 2007;9(12):1003-1011.
42. Reischauer C, Froehlich JM, Koh DM et al. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps: initial observations. Radiology 2010;257(2):523-531.
43. Messiou C, Collins DJ, Giles S et al. Assessing response in bone metastases in prostate cancer with diffusion weighted MRI. Eur Radiol 2011;21(10):2169-2177.
44. Nelson SJ, Kurhanewicz J, Vigneron DB et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C] pyruvate. Sci Transl Med 2013;5(198):198ra108.
45. Scher HI, Halabi S, Tannock I et al. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148-1159.